Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...
Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics Olga Anczukow, Ph.D. Olga Anczukow, Ph.D.
WASHINGTON, Feb 23 (Reuters) - The U.S. Food and Drug Administration proposed on Monday a new framework to speed approvals of ...
The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments ...
Researchers develop a 3D-printed, RNA-activated implant that silences the PTEN gene to promote nerve regrowth after spinal ...
Morning Overview on MSN
Self-building RNA strand may expose how life on Earth truly began
Two separate laboratory breakthroughs have produced RNA molecules that can build copies of themselves or assemble functional structures without any help from proteins or DNA. These results offer the ...
A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
Molecular Instruments® (MI), inventor of the HCR™ technology, today announced the availability of fully ambient-temperature ...
Release summary: Molecular Instruments launches fully ambient-temperature HCR (TM) Pro RNA-ISH on the BOND-III, marking a new generation of clinical-grade RNA-ISH designed to reduce heat-driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results